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Abstract
There is a growing body of evidence that serotonergic antidepressants are useful in the treatment of
maladaptive behaviours in the intellectually disabled. However, not all studies have shown positive
results due to lack of efficacy, tolerance development, and troublesome side-effects. The current study
consisted of a review of the treatment response to a variety of serotonergic antidepressants, consisting of
selective serotonin reuptake inhibitors (SSRIs ) (n=36) and clomipramine (n=2) in 38 institutionalized
intellectually disabled adults (20 males, 18 females ; mean age 45.6 yr, age range 18–74 yr). Those studied
were treated for aggression, self-injurious behaviours, destructive/disruptive behaviours, depression/
dysphoria, or a combination of these or other challenging behaviours. Most were receiving concurrent
psychotropic and/or anticonvulsant medications. Effectiveness was determined by a retrospective review
of the summaries of multidisciplinary Neuropsychiatric Behavioural Reviews (NBRs) in which global and
specific maladaptive behaviours were rated on a 1- to 7-point scale, and by psychologists’ ratings of target
behaviours. Overall, statistically significant decreases in the ratings of global maladaptive behaviour and
aggression, self-injurious behaviour, destruction/disruption and depression/dysphoria and in psychol-
ogists’ ratings occurred in the subject group after the initiation of antidepressants. The results suggest that
serotonergic antidepressants are useful in the treatment of challenging/maladaptive behaviours in the
intellectually disabled.
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Introduction
Intellectual disability is frequently associated with ag-
gression towards self, aggression towards others, and/
or destructive/disruptive behaviours (Baumeister
et al., 1998). Such behaviours occur with increasing
frequency as IQ decreases. Typical or conventional
antipsychotic drugs have traditionally been the front-
line treatment for these challenging behaviours
(Baumeister et al., 1998), and newer ‘atypical ’ anti-
psychotic agents have more recently been used
(Aman, 1999 ; Cohen and Underwood, 1994 ; Horrigan
et al., 1997, Janowsky et al., 2003 ; Lott et al., 1996 ;
Martin et al., 1999 ; McCracken et al., 2002). However,
advances in the diagnosis of mood and anxiety
disorders, and an awareness of the limitations and
dangers of utilizing conventional and atypical anti-
psychotic agents have resulted in a narrowing of
the use of antipsychotic drugs to treat challenging
behaviours.
A number of publications have supported the
possibility that maladaptive behaviours in the intel-
lectually disabled may be attenuated or alleviated by
the administration of serotonergic antidepressant
agents. Such agents include the selective serotonin re-
uptake inhibitors (SSRIs) and the serotonergic tricyclic
antidepressant, clomipramine. The rationale for the
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use of these agents is, in part, that they are effective in
the treatment of depression, anxiety and obsessive–
compulsive disorder in non-intellectually disabled
populations, and thus, may be useful in the intellec-
tually disabled with similar disorders. Significantly,
the above psychiatric disorders may manifest them-
selves as stereotypic, self-injurious, aggressive and
disruptive/destructive behaviours in the intellectually
disabled.
Previously, Gordon et al. (1993) observed that the
selective serotonergic tricyclic antidepressant clomi-
pramine was superior both to placebo and to the non-
serotonergic antidepressant, desipramine in treating
autistic behaviour in 30 subjects aged between 6 and
23 yr. Target behaviours included stereotypic, angry,
compulsive and ritualized behaviours. Similarly,
Lewis et al. (1995, 1996) studied the effects of clomi-
pramine treatment on self-injurious behaviour (SIB) in
studies of 10 and 8 adults respectively with severe
mental retardation, using a double-blind, placebo-
controlled design. These authors observed that clomi-
pramine treatment was associated with improvement
in the intensity of SIB, the frequency of stereotypy and
compulsions, and a decrease in staff-reported inter-
ventions for problem behaviours. Garber et al. (1992)
demonstrated that clomipramine was effective in
decreasing chronic stereotypic and SIB such as head
banging, head and face slapping, arm biting, eye
gouging, aggression and tantrums in 10 out of 11
adolescents with developmental disorders. In a pro-
spective open trial of clomipramine, Brodkin et al.
(1997) observed that 55% of the 33 adults with
Pervasive Developmental Disorder who completed
the 12-wk trial were treatment responders, with
clomipramine reducing repetitive thoughts and
behaviours, aggression and improving social respon-
siveness.
With respect to the SSRIs, Bodfish and Madison
(1993) reported improvement following fluoxetine ad-
ministration of such symptoms as SIB and aggression
in 7 out of 10mentally retarded adults with compulsive
disorders (and none of a group of comparison subjects
without compulsive disorder). Similarly, Markowitz
(1992) reported on the effects of an open trial of
fluoxetine in alleviating aggression and SIB in 21
people who were severely or profoundly mentally re-
tarded, and found improvement in all but two indi-
viduals, with marked improvement occurring in 13.
Consistent with the above results, Fatemi et al. (1998)
reviewed the charts of seven young adults with autistic
disorder treated with fluoxetine. These authors found
improvement in irritability, lethargy and stereotypy.
Similarly, McDougle et al. (1996) observed that
fluvoxamine treatment of 15 autistics was significantly
superior to placebo in reducing repetitive thoughts
and behaviours, maladaptive behaviours, aggression
and in improving social behaviour and languageusage.
In spite of the largely positive results outlined
above, several studies of serotonergic-enhancing
drugs in autistic and in other intellectually disabled
people have not yielded such promising results.
Varley and Holm (1990) found that tolerance to the
serotonergic agent fenfluramine developed in six
children with autism. Davanzo et al. (1998), studying
SIB (i.e. head banging, biting self, hitting self, choking
self, pulling one’s hair) and aggression in 15 insti-
tutionalized people withmental retardation found that
paroxetine only decreased aggression severity early in
a 4-month trial. SIB diminished qualitatively at 1month
and increased above baseline as time passed. Similar
tolerance to or decreasing effectiveness of SSRIs or
clomipramine was noted in persons with Lesch–
Nyhan Syndrome (Nyhan et al., 1980) and Prader–
Willi Syndrome (Dech and Budow, 1991), and in cases
of non-specificmental retardation (Ricketts et al., 1993).
Branford et al. (1998), in a retrospective case analysis
of 37 adults with intellectual disability who received
fluoxetine or paroxetine, found that these SSRIs
proved of no benefit in 40%, and led to deterioration in
25%. Thirty-five per cent showed some reduction in
maladaptive behaviours. Similarly, Ghazuiddin et al.
(1991) noted that SSRI antidepressants, while alleviat-
ing depression, did not seem to effect compulsive
movements and stereotypy.
Finally, a consistent problem noted in many studies
was the development of side-effects such as seizures,
tachycardia, sedation, agitation, obvious worsening of
target symptoms, constipation, irritability, decreased
appetite, increased appetite, and sweating. Asmany as
one third receiving serotonergic antidepressants
developed such side-effects, often necessitating drug
discontinuation (Branford et al., 1998 ; Davanzo et al.,
1998 ; Lewis et al., 1995 ; McDougle et al., 1996;
Sanchez et al., 1996).
In the current study, we retrospectively evaluated
the effectiveness of a variety of serotonin-enhancing
antidepressant drugs (serotonergic antidepressants)
including paroxetine, fluoxetine, fluvoxamine, sertra-
line, citalopram and clomipramine as treatments for
maladaptive target behaviours in severely intellectu-
ally disabled institutionalized adults. Many of those
studied were diagnosed as having bipolar and other
mood disorders, obsessive–compulsive disorder,
autism or impulsive disorders, all of which have been
proposed at one time or another to be caused by ab-
normal serotonin activity.
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Methods
Subjects
Those studied were 38 intellectually disabled adults
who received treatment with a serotonergic anti-
depressant for behavioural purposes. They all were
institutionalized at the Murdoch Center in Butner,
North Carolina, a 580-bed state facility for the treat-
ment of the intellectually disabled where they had
resided from years to decades. They were a subgroup
of a larger group of 225 Murdoch Center residents
treated with one or more psychotropic agents for
behavioural purposes (with or without serotonergic
antidepressants administered) between 1994 and 2000.
To be included in the analysis, the subjects were
required to have had an antidepressant free baseline
evaluation [see Neuropsychiatric Behavioural Reviews
(NBRs) below] and a subsequent evaluation following
serotonergic antidepressant administration for at least
6 wk. Other subjects also received serotonergic anti-
depressants, but did not meet the above criteria (i.e.
some arrived at Murdoch Center already receiving
serotonergic antidepressants) and they were not
included in the analysis.
The maladaptive behaviours treated included
aggression towards others (i.e. hitting, biting, kicking,
shoving, making aggressive threats, etc.), SIB (i.e. self-
hitting, biting, head banging, cutting on one’s skin,
skin picking, skin scratching, etc.), destructive behav-
iours (i.e. overturning or breaking furniture, breaking
windows, etc.), disruptive behaviours (i.e. screaming,
yelling, uncontrollable running, tantrums, inappro-
priate stripping), other behaviours (i.e. masturbation,
rectal digging, crying, whining, agitation, non-partici-
pation, non-compliance) or combinations of the above
such behaviours. Those studied had been treated with
an SSRI or clomipramine. The shortest period was
6 wk. All had a documented record of one or more
maladaptive target behaviours prior to the initiation
of the serotonergic antidepressant. There were no
specific exclusion criteria.
The characteristics of the 38 adults studied are listed
in Table 1. Subjects consisted of 20 males and 18
females. Their mean age was 45.6 yr, with an age range
of 18–74 yr. Twenty-sevenwere Caucasian and 11were
African American. Over the years most had been as-
signed psychiatric diagnoses (generally made utilizing
DSM-III-R or DSM-IV descriptions) based on clinical
evaluations and psychiatric symptoms listed in the
subjects’ charts. These included Bipolar Affective
Disorder,MajorDepressiveDisorder,MoodDisorder –
NOS, Autism, Schizophrenia, Behavioural Disorder –
NOS, and Conduct Disorder. All individuals studied
had co-existing medical disorders and 19 had a seizure
disorder. Twenty-eight had been evaluated as having
profound cognitive intellectual disability, six tested
in the severe range and four tested in the moderate
range. Thirty showed profound, six showed severe,
Table 1. Diagnostic and demographic data on 38
intellectually disabled institutionalized adults receiving
serotonergic antidepressants
Case
no. Age (yr), race, gender Diagnosis
1 30, AA, Male BPAD, Dep
2 68, AA, Female Behav Dis
3 36, W, Male Autism
4 30, W, Male Autism
5 50, W, Male Autism
6 36, AA, Female Schiz
7 22, W, Male Behav Dis, Autism
8 32, W, Female No diagnosis
9 54, W, Male Autism
10 47, W, Male BPAD
11 33, AA, Female Dep
12 49, AA, Female No diagnosis
13 52, AA, Male Behav Dis, Schiz
14 45, W, Female BPAD
15 22, AA, Male Explosive Dis
16 52, W, Female BPAD
17 18, W, Male Autism
18 71, W, Female Conduct Dis
19 74, W, Female Mood Dis
20 36, AA, Male Dep, Disrup Dis
21 42, W, Female BPAD
22 35, W, Male Behav Dis
23 72, AA, Female BPAD, Behav Dis
24 45, W, Female OCD, Schiz
25 79, W, Female OCD, Autism
26 57, W, Male Language Dis
27 50, W, Male OCD, Schiz
28 56, W, Female Affective Dis
29 70, W, Female BPAD
30 48, W, Male Major Dep
31 50, AA, Male No diagnosis
32 42, W, Female Dep
33 24, W, Male Behav Dis
34 33, W, Female OCD, Autism, BPAD
35 53, W, Female Behav Dis
36 35, AA, Male Mood Dis NOS
37 52, W, Male Personality Dis
38 43, W, Female BPAD
AA, African American ; W, white ; BPAD, bipolar affective
disorder ; Behav, behavioural ; Dis, disorder ; Dep,
depression ; Disrup, disruptive ; OCD, obsessive–compulsive
disorder ; Schiz, schizophrenia.
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and two showed moderate adaptive intellectual dis-
ability.
Medications
Decisions to use medications for behavioural purposes
were made in approximately quarterly (or more
frequently as clinically indicated) multidisciplinary
NBR conferences that occurred between the years 1994
and 2000. In these conferences, a careful weighing
of the pros and cons of instituting, continuing, mod-
ifying or stopping psychotropic medications was
made. Final authorization to use a medication for
psychotropic purposes was obtained from subjects’
guardians prior to beginning treatment. Ultimately,
orders were written by the subjects’ primary-care
physicians, with dosing based on consideration of
medical status, other medications utilized, and toler-
ance of the medication.
Those studied were most often placed on an SSRI or
clomipramine because of an incomplete response to
other psychopharmacological agents, or because of a
desire to eliminate drugs that were causing or could
cause unacceptable side-effects such as tardive dys-
kinesia. As shown in Table 2, of those studied, 14 re-
ceived paroxetine, 9 received fluvoxamine, 7 received
sertraline, 5 received fluoxetine, 1 received citalopram
and 2 received clomipramine. Twenty-eight of those
studied also received one or more other medications
for psychotropic or anti-seizure purposes. These
medications included thioridazine, mesoridazine,
haloperidol, thiothixene, clonazepam, olanzapine,
lithium, topiramate, depakote, propranolol, gaba-
pentin and carbamazepine.
Prior to beginning the study, authorization to
review subjects’ records was obtained from the
University of North Carolina at Chapel Hill
Institutional Review Board and the Murdoch Center at
Butner, North Carolina, Research Review Committee.
All those studied had been administered a behav-
ioural intervention programme (BIP) prior to begin-
ning the study, and all continued on the BIP
throughout the study.
NBR record evaluations
Utilizing retrospective reviews (see Janowsky et al.,
2003), the NBR conference records of the 38 residents
of Murdoch Center to whom a serotonergic anti-
depressant had been administered between years 1994
and 2000, and who were still continuing to receive
psychotropic medications in the year 2000 were sys-
temically reviewed. The NBR conferences consisted of
required meetings of a subject’s treatment team, which
occurred approximately quarterly or more frequently
depending on clinical considerations. In the NBR
conference, the treatment team, consisting of a cottage
manager, psychologist, nurse(s), nursing assistant(s),
primary-care physician, pharmacist, educator and
consulting psychiatrist reviewed the progress and
evaluated responses to psychotropic medications of
the individuals in question, focusing on overall
behaviour and specific target behaviours.
The conference had a special focus on the utilization
of medications given for the purpose of minimizing
maladaptive behaviours. During each conference, a
written summary reviewing the course and changes
since the last NBR was presented by the nursing
and other treatment staff. The summary consisted of :
(1) the subject’s behavioural diagnosis, (2) psycho-
tropic and other medications given and changes in
medications made since the last NBR conference,
(3) significant adverse or side-effects noted since the
last review, (4) significant laboratory tests and serum
drug levels noted, (5) weight changes (data obtained
monthly), (6) details of changes in target symptoms,
(7) any changes in behavioural intervention plans,
(8) monitoring methods and (9) progress towards
goals and continuing status of skills. A verbal
summary of progress was also given by the treatment
staff, and a longitudinal quantitative graphing of
specific target behaviours was provided by the unit
psychologist.
From this NBR conference a permanent report was
generated by the consulting psychiatrist or by the
subjects’ primary-care physician when the psychiatrist
was not present, and it was these NBR conference
reports that were reviewed as sources of data for the
current study.
Psychologists’ ratings
The frequency of aggressive, self-injurious and dis-
ruptive/destructive target behaviours was evaluated
by totalling the cumulative longitudinal graphed
observations of specific target behaviours, as provided
at the NBR conferences by the unit psychologists. The
cumulative number of recorded specific target behav-
iours, as graphed by the unit psychologist was evalu-
ated for the month before beginning the serotonergic
antidepressant (baseline) and the month leading up to
the last reviewed NBR following the administration of
a serotonergic antidepressant. In addition, a ‘most
severe behavioural score’ was recorded, consisting of
the baseline behaviour which had the highest fre-
quency. Not all target behaviours occurred in every
subject, and the methods of evaluation for a given
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target behaviour differed from unit to unit, psychol-
ogist to psychologist, and between the individuals
observed. Longitudinal graphs were obtained for 14 of
the 38 subjects (see Table 3).
Global ratings
NBR summaries were retrospectively evaluated for
overall severity of maladaptive symptoms by one of us










Baseline Post-drug time 1 or 2
1 Paroxetine 20 mg 30 mg Lithium, Depa Same
2 Fluvoxamine 12.5 mg 12.5 mg Top Same
3 Fluvoxamine 12.5 mg 50 mg Thior Same
4 Paroxetine 20 mg 40 mg Thior Same
5 Fluvoxamine 125 mg 200 mg Thior Same
6 Paroxetine 20 mg 30 mg Thior Same
7 Paroxetine 10 mg 20 mg Lithium Lithium, Gaba
8 Paroxetine 20 mg 20 mg Carb Same
9 Fluvoxamine 12.5 mg 12.5 mg None None
10 Sertraline 100 mg 50 mg Lithium, Carb Same
11 Paroxetine 10 mg 20 mg None None
12 Sertraline 75 mg 75 mg None None
13 Fluoxetine 5 mg 5 mg Clonazepam Same
14 Clomipramine 75 mg 125 mg Mesoridazine, Carb Same
15 Fluvoxamine 25 mg 25 mg Thiot Same
16 Paroxetine 20 mg 20 mg None None
17 Fluvoxamine 12.5 mg 12.5 mg None Temazepam
18 Sertraline 50 mg 75 mg Thiot, Lithium, Depa Same
19 Fluoxetine 2 mg 8 mg None None
20 Fluvoxamine 25 mg 25 mg Thiot, Lithium, Prop Same
21 Paroxetine 20 mg 30 mg Haloperidol, Carbb Same
22 Paroxetine 20 mg – Haloperidol –
23 Fluoxetine 20 mg 20 mg Thior Same
24 Fluvoxamine 25 mg 100 mg Haloperidol, Thior Same
25 Sertraline 125 mg 200 mg Carb Same
26 Paroxetine 20 mg 40 mg None Lorazepam
27 Clomipramine 50 mg 75 mg Haloperidol, Depac Same
28 Fluoxetine 20 mg 20 mg Depa Same
29 Sertraline 50 mg 50 mg Thior, Lithium Same
30 Sertraline 50 mg 50 mg Depa Same
31 Paroxetine 20 mg 20 mg Thiorc, Olanb, Top Same
32 Citalopram 20 mg – Prop –
33 Paroxetine 20 mg – Thior, Gaba –
34 Fluvoxamine 12.5 mg 12.5 mg None None
35 Paroxetine 20 mg – None –
36 Fluoxetine 40 mg 40 mg Thior, Carb Thior
37 Sertraline 100 mg 100 mg None None
38 Paroxetine 20 mg 20 mg Thior, Lithium Same
Depa, depakote ; Carb, carbamazepine ; Gaba, gabapentin ; Thior, thioridazine ; Thiot, thiothixene ; Prop, propranol ; Olan,
olanzapine ; Top, topiramate.
aMean time in months (mo.) after beginning antidepressant medications.
b A decrease in dosage occured.
c An increase in dosage occured.
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(D.S. J.) using a 1- to 7-point global behavioural rating
scale. For this scale, 1–2=none to mild symptoms,
3–5=moderate symptoms, and 6–7=severe symp-
toms. Since in initially constructing the global scale we
were not sure that we could accurately discriminate at
the lower end of the scale, a plus (+) or minus (x) was
utilized. For purposes of data analysis, each (+) added
0.25 points, and each (x) subtracted 0.25 points. The
global severity scale roughly paralleled the Severity of
Illness component of the Clinical Global Impressions
Scale (NIMH, 1985).
Quotes from NBR records illustrating mild and
severe symptoms respectively are as follows:
Case no. 4 (Baseline)
has had minor aggressions. However, has been doing well in
terms of aggression and more worrisome behaviours
(score=2.0).
Case no. 25 (Baseline)
continues to have marked tissue injury which has resulted in
medical treatment. Continues to have significant aggression
toward others (score=6.25).
For purposes of data analysis of the 1- to 7-point global
behavioural rating scale, NBRs were divided into four
time-points. The ‘Pre-baseline’ time-point was the
NBR closest to 3 months before beginning the seroto-
nergic antidepressant [mean=x3.04¡0.82 months
(mean¡ S.D.)]. The ‘Baseline’ time-point was the NBR
occurring just prior to starting serotonergic anti-
depressants. ‘Post-drug time 1’ was the NBR closest
to 3 months after beginning antidepressant treatment
(mean=+3.39¡0.83 months) and ‘Post-drug time 2’
was the NBR closest to 6 months after beginning
serotonergic antidepressants (mean=+6.24¡1.55
months). Not all subjects had data for the Pre-baseline
time-point or Post-drug time 2, but all had data for
the Baseline and Post-drug time 1 time-points (see
Table 4).
In addition to the global behavioural ratings, ag-
gression, SIB, destruction/disruption and depression/
dysphoria were evaluated by one of us (D.S. J.) using
the 1- to 7-point scale if these behaviours were
mentioned in a given NBR report (see Table 5).
To ascertain the reliability of the behavioural ratings
made by the first author (D.S.J.), two of the authors
[rater no. 1 (M.S.) and rater no. 2 (J.M.D.)] indepen-
dently rated approx. 20% of the quarterly NBR
evaluations. For the global behavioural rating scale,
Pre-baseline, Baseline, Post-drug time 1, and Post-drug
time 2 ratings for rater no. 1 correlated 0.86, 0.93, 0.82,
0.96 respectively with those of the first author. For
rater no. 2 these correlations were 0.98, 0.92, 0.97 and
0.89. In addition, rater no. 2 evaluated the above
subgroup of NBRs for aggression, SIB, destruction/
disruption and depression/dysphoria. These ratings
were correlated with the first author’s ratings. Inter-
class correlations were calculated by a two-way
mixed-effects model with subjects randomized and
measures fixed. The inter-class correlations for ag-
gression, SIB, destruction/disruption and depression/
dysphoria were 0.96, 0.83, 0.75 and 0.75 respectively.
Statistical analysis
Changes in the psychologists’ ratings were evaluated
using the Wilcoxon matched-pairs sign-rank test. With
respect to the global ratings, since the variance of the
different time phases was equal (Wilcoxon test), as
determined using Levine’s test of homogeneity of
variance (p=0.162) we proceeded with an analysis of
Table 3. Psychologists’ cumulative aggressive, self-injurious,
destructive/disruptive and most severe scores in the
month before baseline and in the month before the last
Neuropsychiatric Behavioural Review (NBR) in 14 out of







Pre Post Pre Post Pre Post Pre Post
2 40 5 0 0 40 5 – –
9 60 35 1 0 60 35 – –
10 200 48 0 0 – – 200 48
13 500 50 20 25 500 50 – –
17 70 50 – – 6 6 70 50
25 25 2 8 5 25 2 5 0
26 10 0 – – – – 10 0
28 15 30 15 30 – – 12 5
29 29 9 2 0 – – 29 9
31 30 20 5 2 – – 30 20
33 21 4 – – – – 21 4
34 31 4 – – 31 4 – –
35 17 15 – – 15 20 17 15
36 10 2 10 2 – – 2 1
Means 75.6 19.6 6.8 7.1 96.7 17.4 39.6 15.2
SIB, Self-injurious behaviour.
Scales utilized by the psychologists varied from person to
person and from unit to unit. Pre=the cumulative ratings of
the month before the baseline NBR; post=the cumulative
ratings of the month before the last NBR during which anti-
depressants were administered (i.e. the last evaluated post-
drug time-point).
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variance to see if any difference existed between the
various means. A post-hoc analysis of the difference
between the time-points was determined using a
Bonferroni (Dunn) t test, since the numbers in each
group compared differed.
Percentage changes between Baseline and the global
behavioural ratings for Post-drug time 1 and Post-drug
time 2 respectively were calculated for each subject,
and differences between the number of subjects
showing a o25% decline in scores vs. the number




















1 1.75 2.00 1.00 2.75 x50 +38
2 – 3.25 2.25 2.25 x31 x31
3 3.00 3.00 3.00 2.00 0 x33
4 1.75 2.00 2.00 1.25 0 x38
5 3.25 2.75 2.25 2.25 x18 x18
6 2.25 2.25 2.25 1.25 0 x44
7 3.25 3.25 2.25 2.25 x31 x31
8 3.25 3.75 2.75 2.25 x27 x40
9 4.25 6.00 5.00 5.00 x17 x17
10 4.00 3.25 3.00 2.75 x8 x15
11 – 4.25 2.25 2.25 x47 x47
12 – 4.25 2.25 2.75 x47 x35
13 6.00 6.00 2.25 3.00 x63 x50
14 3.25 4.00 4.00 4.00 0 0
15 6.00 6.00 2.25 3.00 x63 x50
16 3.00 3.00 1.75 1.75 x42 x42
17 3.25 3.25 2.75 2.00 x15 x38
18 3.75 3.75 3.00 2.00 x20 x47
19 – 3.25 3.25 3.00 0 x8
20 4.75 6.25 2.25 3.25 x64 x48
21 4.00 4.25 3.00 2.75 x29 x35
22 3.00 3.75 3.75 – 0 –
23 3.75 3.75 3.00 4.25 x20 +13
24 5.00 6.00 4.00 4.25 x33 x29
25 6.00 6.25 4.25 3.25 x32 x48
26 – 3.25 1.75 1.25 x46 x62
27 2.75 3.75 3.75 3.25 0 x13
28 – 3.25 2.00 3.25 x38 0
29 2.25 3.75 2.25 2.75 x40 x27
30 4.00 3.75 3.25 2.25 x13 x40
31 4.00 4.25 3.25 3.25 x24 x24
32 3.00 5.00 2.25 – x55 –
33 5.00 4.00 4.25 – +6 –
34 6.00 6.00 2.25 2.25 x63 x63
35 – 4.75 5.75 – +21 –
36 5.25 6.00 5.00 2.75 x17 x54
37 3.75 4.00 3.25 3.00 x19 x25
38 – 4.25 4.25 3.00 0 x29
Means 3.8 4.1 2.9 2.7 x24.8% x30.3%
Global severity was rated on a 1- to 7-point scale ranging from none to severe maladaptive behaviour. Percentages rounded off
to nearest whole number.
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showing a o25% increase in scores were compared
using a sign test.
In addition, baseline post-differences between
various specific behaviours (i.e. aggression, SIB,
destruction/disruption, depression/dysphoria and
‘most severe’ behavioural score’) were evaluated
using the Wilcoxon matched-pairs sign-rank test,
comparing Baseline with the last evaluated post-drug




Most severe Aggression SIB Disruption Depression
Pre Post Pre Post Pre Post Pre Post Pre Post
1 2.25 1.75 – – – – – – 2.25 1.75
2 3.00 2.00 3.00 2.00 3.00 2.00 – – – –
3 4.00 2.75 1.25 1.25 – – 4.00 2.75 – –
4 2.25 2.00 2.25 2.00 – – – – – –
5 3.25 3.25 – – – – 3.25 3.25 – –
6 3.00 1.75 – – – – 2.25 3.25 3.00 1.75
7 3.25 1.75 – – – – – – 3.25 1.75
8 3.25 2.25 2.75 3.25 3.25 2.25 – – 3.00 1.75
9 6.25 4.25 – – 6.25 4.25 – – 2.75 2.25
10 4.00 3.00 – – – – 4.00 3.00 – –
11 4.25 2.25 – – – – 4.25 2.25 – –
12 5.00 3.00 – – – – – – 5.00 3.00
13 6.00 3.00 5.00 3.00 6.00 3.00 – – – –
14 4.00 4.00 – – 3.00 3.00 4.00 4.00 – –
15 6.00 2.75 6.00 2.75 – – – – – –
16 3.00 1.25 – – – – 3.00 1.25 3.00 1.25
17 3.00 2.00 – – – – 3.00 2.00 – –
18 3.25 2.00 2.25 1.00 3.25 2.00 – – 3.25 2.00
19 3.75 3.00 – – 1.00 1.00 3.75 3.00 3.75 3.00
20 5.00 3.00 5.00 3.00 5.00 3.00 5.00 3.00 – –
21 5.00 4.00 – – 5.00 4.00 – – 3.25 2.00
22 2.75 2.75 – – 2.75 2.75 – – – –
23 4.00 4.25 – – – – – – 4.00 4.25
24 6.00 4.00 – – 6.00 4.00 – – – –
25 7.00 3.25 7.00 3.25 6.00 3.00 5.00 2.25 – –
26 3.25 1.75 – – – – – – 3.25 1.75
27 2.25 3.00 2.75 3.00 – – 2.75 2.75 – –
28 3.00 3.00 – – – – 3.00 3.00 3.00 2.00
29 3.25 2.25 – – – – 3.25 2.25 – –
30 3.00 2.25 – – – – 3.00 2.25 – –
31 4.25 3.00 2.75 2.25 – – – – 4.25 3.00
32 4.00 2.00 – – 3.00 2.00 4.00 2.00 4.00 2.00
33 3.25 5.25 1.25 3.00 1.75 3.25 3.25 5.25 – –
34 6.75 2.00 5.00 2.00 6.75 2.00 5.00 2.00 – –
35 4.00 5.00 – – – – 4.00 5.00 – –
36 5.75 2.25 5.75 2.25 – – – – 5.00 1.75
37 3.25 2.25 3.25 2.25 3.25 2.25 3.25 2.25 – –
38 5.25 3.00 2.75 2.25 4.00 2.75 3.00 2.25 5.25 3.00
Means 4.04 2.79 3.62 2.41 4.07 2.73 3.62 2.80 3.60 2.25
SIB, Self-injurious behaviour.
Each specific behaviour was rated on a 1 - to 7-point scale ; Pre=baseline, Post=last evaluated post-drug time-point (i.e.
post-drug time 1 or 2).
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NBR (i.e. either Post-drug time 1 or Post-drug time 2).
Significance was set at an alpha of 0.05 or lower using
two-tailed tests.
Results
Table 3 presents the psychologists’ longitudinal beha-
vioural ratings of the target symptoms of aggression,
SIB, destruction/disruption and the most severe be-
havioural score. Cumulative ratings for the month
before beginning serotonergic antidepressants and the
month before the last evaluated NBR after the begin-
ning of serotonergic antidepressants were compared.
An overall decrease in the ‘most severe behavioural
score’ was statistically significant (p<0.001, Wilcoxon
sign rank test). The changes in scores of the psychol-
ogists’ aggression ratings was not significant (p=ns).
SIB ratings decreased significantly (p=0.048), as did
destruction/disruption ratings (p=0.005).
Table 4 outlines the individual global behavioural
rating scale scores and their group means¡standard
deviations obtained from the NBRs occurring before
and after beginning serotonergic antidepressants.
Overall, a significant change over time occurred in the
global behavioural ratings as determined by one-way
ANOVAs (F1,3=12.81, d.f.=3, p<0.0001). Since the
one-way ANOVA revealed a significant overall dif-
ference in the means at the different time-points, we
determined which individual means for a given time-
point differed from the others. We ran multiple
comparisons of the means using the Bonferroni
(Dunn) t test, since the numbers in each group differed
from each other. The differences in means between
the Pre-baseline and Baseline time-points and Post-
drug time 1 and Post-drug time 2 respectively were
not statistically significant. The difference between
the Pre-baseline ratings and Post-drug time 1 was
statistically significant (p=0.014), as was the difference
between the Pre-baseline time-point and Post-
drug time 2 (p<0.001). The difference between the
Baseline time-point and Post-drug time 1 was statisti-
cally significant (p<0.001), as was the difference
between the Baseline time-point and Post-drug time 2
(p<0.001).
As shown in Table 4, by defining antidepressant
efficacy as a decrease of 25% or more in the global
behavioural score between the Baseline time-point and
Post-drug time 1, 18 out of 38 (47.4%) showed ao25%
decrease in global behavioural ratings (mean decrease
=x24.8%) and six of this group showed decreases of
50% or more. Comparing the Baseline ratings with
Post-Drug time 2, 24 out of 34 subjects (70.6%) showed
a decrease of 25% or more (mean decrease=x30.3%),
and five showed a decrease of 50% or more. In con-
trast, only one individual showed a clinically signifi-
cant increase in the global rating scale of >25%
(significance on exact binomial distribution, p<0.0001
and p<0.0001 respectively).
Table 5 shows the ratings of the Baseline time-point
and Post-drug time 1 or Post-drug time 2, whichever
occurred last, for aggression, SIB, destruction/
disruption and depression/dysphoria and the ‘most
severe’ behavioural score, as rated by D.S.J. Signifi-
cant decreases occurred in aggression (p=0.007),
SIB (p<0.001), destruction/disruption (p<0.015),
depression/dysphoria (p<0.001), and ‘most severe
behavioural ’ (p<0.001).
Several physical and behavioural side-effects were
observed during administration of the serotonergic
antidepressants. Acne occurred in one individual and
constipation occurred in another. Administration of
serotonergic antidepressants led to a significant
worsening of target symptoms in four of the subjects
(subject nos. 22, 23, 33, 35), eventually leading to a
termination of medications. In addition, subject no. 3
had previously experienced a similar negative reaction
to fluoxetine, but later tolerated fluvoxamine, and
subject no. 32 showed an increase in symptoms with
fluoxetine, but later tolerated citalopram. Twenty-four
individuals had NBR reports that contained enough
data to compare baseline weights with weights
after serotonergic antidepressant administration. Base-
line weights averaged 131.5 lb, whereas post-anti-
depressant (Post-drug times 1 or 2) weights averaged
135.4 lb. Seven of the subjects gained 10 lb or more
after beginning antidepressant therapy, whereas only
one lost 10 lb or more. No increase in seizure activity
was noted during serotonergic antidepressant admin-
istration, nor was there a need to increase anti-seizure
medications.
Discussion
This paper outlines our evaluation of the adminis-
tration of serotonergic antidepressants in an in-
stitutionalized intellectually disabled population. The
decision to begin a SSRI or clomipramine was based
on clinical factors. In our evaluation, we did not
exclude any subjects based on diagnosis, age, level
of intellectual disability, or associated neurological
symptoms. Thus, this study reflects the ‘real world’ of
treatment of institutionalized people who are severely
or profoundly intellectually disabled and who have
maladaptive behaviours.
The principal finding of this study is that seroton-
ergic antidepressants caused a statistically significant
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decrease in the psychologists’ behavioural ratings,
in global ratings of maladaptive behaviour and in
aggressive, self-injurious, and destructive/disruptive
behaviours and in depression/dysphoria. Analysis of
individual results showed that a significant percent-
age of the study population had a clinically significant
(>25%) reduction in their global ratings. Responders
did not appear to differ from non-responders on any
of the demographic or diagnostic characteristics
examined, or on the drug or the drug doses used.
The antidepressants in the doses used were rela-
tively well tolerated, with the majority of those treated
remaining on medication for 6 months or more.
Overall, improvement continued over the 6-month
study period, with little evidence of tolerance devel-
opment. However, several of the subjects experienced
an activation of target symptoms while on seroton-
ergic antidepressant medications, leading to medi-
cation discontinuation.
The current study has a number of limitations. The
group studied was relatively small, in spite of the
study having been the largest we have found per-
formed to date. The results were based on data ob-
tained retrospectively from chart reviews. Behavioural
data were not formally correlated with information
related to the status of each patient’s affective disorder
or other symptoms (i.e. sleep patterns, affective state,
etc.). Many of the subjects required and were ad-
ministered additional psychotropic medications and/
or anti-seizure medications before or while being
given antidepressant drugs. It is likely that partial
therapeutic effects had been reached by the adminis-
tration of these psychotropic medications in many of
the subjects before antidepressant medication was
started.
In a minority of our subjects other psychotropic
drugs were changed or started during the time that the
serotonergic antidepressants were administered (see
Table 2). Therefore, in such cases, attribution of
ameliorative effects to a serotonergic antidepressant
was complicated by the possible therapeutic effects of
the additional medication or medication changes.
Furthermore, in cases where other psychotropic
medications were administered prior to the time that
a serotonergic antidepressant was given, addition of
a serotonergic antidepressant could have led to metab-
olic changes leading to increased and/or more effec-
tive blood levels of the original compound or vice
versa, or to synergistic effects.
Surprisingly few side-effects were noted in the study
following serotonergic antidepressant administration.
The fact that those studied were largely non-verbal
may have, in part, led to an under-reporting of drug
side-effects. Also, the nursing staff tended to note only
serious side-effects at the NBR conferences. Since no
formal monitoring system focusing on side-effects was
in place, it is difficult to tell if more subtle side-effects
actually occurred and were not detected.
The study did not include placebo controls, and no
blinding of drug treatment occurred. However, con-
versely, the treated individuals were not subjected to
the disadvantages of a washout period, such as occurs
in most controlled studies. A washout strategy has the
potential for causing an increase in baseline symptoms
due to withdrawal (i.e. rebound) effects or the un-
masking of suppressed symptoms. An on/off/on de-
sign, with antidepressant added to existing treatments
would have added valuable data as to improvement or
worsening. Alternatively, an add-on design, giving
either serotonergic antidepressant or placebo on a
blinded basis and keeping all other medications un-
changed might also have yielded useful data.
Although multiple drugs were often used in the
treatment of our subject group, thus making difficult
the ascertainment of ‘pure’ effects, this situation does
approximate the clinical situation that occurs com-
monly when challenging behaviours exist. In addition,
since the subjects were all being treated with BIPs, our
study actually is a trial of antidepressant medications
given jointly with behavioural interventions and is not
a ‘pure’ medication trial as such.
In our study, the nature of specific target behaviours
varied from person to person. Use of standardized
rating scales would have added an important analyti-
cal dimension, augmenting the more idiosyncratic but
well-tailored observations that were made.
It should be noted that our subject group scored on
average in the middle range of the 1- to 7-point global
behavioural rating scale. Thus, for the most part, the
subjects showed a moderate degree of maladaptive
behaviours at baseline and the decrease in the behav-
iours following antidepressant treatment was rela-
tively small. Conversely, however, even small changes
in challenging behaviours may be clinically signifi-
cant.
Since most of the subjects were non-verbal, as well
as severely or profoundly retarded, clinical diagnoses
had been made relying heavily on observations of
changes in rates of target behaviours, cyclic with-
drawal or crying, whining, agitation or cyclic associ-
ated sleep disturbances. These diagnoses were
obviously more impressionistic and less reliable than
would occur in general psychiatric or more verbal
populations.
It is important to note that developmentally dis-
abled populations may have distinct sensitivities and
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adverse reactions to psychotropic medications, due to
central nervous system damage, metabolic, pharmaco-
dynamic and pharmacokinetic differences. This
population, being as vulnerable as it is and lacking
legal competence, requires special consideration
before any psychotropic medication is started, and
requires subsequent careful review and monitoring
once administration begins.
In spite of the above limitations, our observations
do suggest that overall, serotonergic antidepressants,
at the doses given in our study, improve maladaptive
behaviours in a population of developmentally dis-
abled adults. This improvement continued over a
period of at least 6 months. Further prospective
studies are suggested, using a larger number of in-
dividuals, placebo controls, and possibly a more dis-
turbed subject population.
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